Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | ANPEP | P15144 | 2/20 | 0.34 |
| ▸ | PPM1D | O15297 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30591269 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2MMP2ANPEPPPM1D | |
| SCHEMBL29304448 | 0.85 | PPM1D (0.36) | PPM1D | |
| SCHEMBL4146529 | 0.84 | MMP2 (0.35) | SMN1; SMN2MMP2ANPEPPPM1D | |
| SCHEMBL13435552 | 0.84 | MMP2 (0.35) | SMN1; SMN2MMP2ANPEPPPM1D | |
| SCHEMBL19964285 | 0.84 | MMP2 (0.35) | SMN1; SMN2MMP2ANPEPPPM1D | |
| SCHEMBL12429348 | 0.82 | MMP2 (0.42) | SMN1; SMN2MMP2ANPEP | |
| SCHEMBL4139942 | 0.82 | MMP2 (0.52) | MMP2ANPEP | |
| SCHEMBL15130169 | 0.82 | MMP2 (0.39) | SMN1; SMN2MMP2ANPEPPPM1D | |
| SCHEMBL8098466 | 0.81 | MMP2 (0.33) | MMP2ANPEP | |
| SCHEMBL14663328 | 0.81 | MMP2 (0.34) | MMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, EIF2AK2, PREP | SMN1; SMN2 3001/4885MMP2 94/4885ANPEP 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.